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Abstract
To assess the efficacy of radioimmunotherapy (RIT) with 90yttrium-ibrutinib-tiuxetan (90Y-IT) in mantle cell lym-
phoma, data from 90 patients registered in the RIT Network with a median follow-up (FU) of 5.5 years after RIT
were evaluated. 90Y-IT was given as first-line therapy in 45 (50%) and for relapse in 45 (50%) patients. Most
patients received 90Y-IT as consolidation after chemoimmunotherapy in first line (98%) and in relapse (53%). As a
first-line treatment, 30 patients (pts.) (67%) achieved CR, 10 pts. (22%) PR%. and 1 pt. (2%) PD, and for 4 pts.
(9%), no response data was available. At relapse, CR was achieved in 17 pts. (38%), PR in 6 pts. (13%), SD in 2
pts. (4%), and 6 pts. (13%) had PD, while the response was not documented for 14 pts. (31%). After a median FU
of 5.5 years, median PFS for all patients was 2.11 (95% CI, 1.03–2.32) years, and median OS was 4.05 (95% CI,
2.79–7.21) years. Eleven pts. (12.2%) developed second malignancy. In conclusion, this is the largest report of MCL
pts. treated with 90Y-IT to date. 90Y-IT was most often used as consolidation after first- and second-line chemo-
therapy and may improve the results achieved using chemoimmunotherapy alone. However, the results are less
encouraging compared to treatment with small molecules such as ibrutinib.
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Introduction
Mantle cell lymphoma (MCL) is a radiosensitive disease.
Current guidelines recommend involved field radiotherapy
(IF-RT) in patients with limited non-bulky stages I and II
tumours, preferably as consolidation after a shortened con-
ventional chemotherapy [1]. However, the majority of MCL
patients are diagnosed during stage III or IV and are treated
with a chemoimmunotherapy, including the anti-CD20 anti-
body rituximab alongside a chemotherapy, which is chosen
according to the performance status of the patient. Younger,
more fit patients are treated with induction chemotherapy
followed by high-dose chemotherapy (HCT) and autologous
stem cell transplantation (ASCT), while less fit individuals
receive treatments such as R-CHOP (rituximab, cyclophos-
phamide, doxorubicin, vincristine, prednisone), R-B (rituxi-
mab bendamustine), or R-CAP (rituximab, bortezomib, cy-
clophosphamide, doxorubicin, prednisone). Recently, addi-
tion of rituximab maintenance therapy has led to a survival
benefit for patients treated with R-CHOP alone or in combi-
nation with HCT and ASCT [2, 3]. Radioimmunotherapy
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(RIT) with the anti-CD20 antibody ibritumomab connected
with tiutexan to the radionucleotide 90yttrium combines
immuno- and radiotherapy treatment modalities. 90yttrium-
ibritumomab-tiuxetan (90Y-IT) (Zevalin®) is approved for
the treatment of follicular lymphoma, i.e. as consolidation
after first-line chemo(immuno)therapy or at relapse. 90Y-IT
can be applied in an outpatient setting. Side effects are well
managed, most frequently occurring is cytopenia between
weeks 6 and 9 after treatment, and infections are not common
as well as need for transfusions.
Currently, 90Y-IT is not licensed for the treatment of
mantle cell lymphoma (MCL). There are published data
from only a few prospective small clinical trials in first
[4, 5] or later therapy lines [6]. Furthermore, data of
long term follow in view of progression-free survival
(PFS), overall survival (OS) and secondary malignancies
are missing. In 2006, the RIT network (RIT-NT) was
founded as a web-based registry using an electronic data
capture system for patients B cell non-Hodgkin’s lym-
phoma (NHL) treated with radioimmunotherapy. We
show here the results of 90 patients with MCL regis-
tered in the RIT-NT treated with 90Y-IT with a medium
follow-up of 5.5 years.
Patients and methods
Between December 2006 and November 2009, the RIT-
NT was active in 14 countries. The RIT-NT evolved
from pre-existing national RIT registries in Spain,
Austria, Switzerland and Germany. A web-based elec-
tronic data capture (EDC) system was utilized for doc-
umentation of the patients. The main dataset includes
indication, age, haematologic toxicity, lymphoma sub-
type and clinical course. For the evaluation of specific
projects, such as the here presented, datasets from na-
tional registries were brought together with the interna-
tional databases. National approval of the ethics com-
mittees (EC) was received by the respective national
RIT registry chairs. Written informed consent of patients
was mandatory. Data was collected and stored de-
identified in the database of the registry. An institutional
IRB vote was provided by the EC of the University of
Göttingen.
The registry is maintained by a professional clinical re-
search organization (CRO; Alcedis GmbH, Giessen,
Germany). Further information regarding the EDC system
has been published recently [7]. For the analysis presented
here, all initially participating centres with documentedmantle
cell lymphoma (MCL) patients in the RIT-NTwere contacted
via mail to take part in the extended follow-up for MCL. For
documentation, the web-based electronic data capturing
(EDC) system was used.
Results
Data from 1105 lymphoma patients treated between
D e c e m b e r 2 0 0 6 a n d N o v e m b e r 2 0 0 9 w i t h
radioimmunotherapy were documented in the RIT-NT. Out
of these 1105 patients, 135 suffered from MCL. Six countries
participated with 90 patients in the elongated follow-up anal-
ysis (Poland n = 53, Germany n = 24, South Korea n = 4, Italy
n = 4, Switzerland n = 3 and Argentina n = 2), while centres
from 8 countries that initially participated in the registry chose
not to participate in the report of longer follow-up data for
unknown reasons. Follow-up analysis included progression-
free survival, overall survival, relapse therapy and second
malignancy.
Patient and disease characteristics
Median follow-up for the 90 MCL patients treated with 90Y-
IT was 5.5 years (range 0 to 11.5 years). Median age at diag-
nosis was 63 years (range 31–78 years), 62% of patients were
older than 60 years, and 21% were above 70 years. Seventy
percent of patients were male, and only 30% were female
(Table 1). Tumour stage was documented only upon initial
diagnosis. Using the AnnArbor classification, 69% of patients
had stage IV, 24% stage III, 2% stage II and 3% stage I disease
(Table 1). The MIPI score, bulky disease and extranodal in-
volvement information were not on hand, because neither the
MIPI score nor the required variables are incorporated in the
documentation of the RIT-NT.
Previous therapies
In this study, first-line therapy is specified as RIT for primary
treatment (monotherapy) or as consolidation after first-line
treatment with chemo- or chemoimmunotherapy. Relapse is
specified as 90Y-IT given as a monotherapy for relapsed or
r e f r a c t o r y M C L , a s c o n s o l i d a t i o n a f t e r
chemo(immune)therapy or as section of a conditioning regi-
men prior to autologous stem cell transplantation. RIT was
given as first-line therapy in 45 patients (50%) and for relapse
in 45 individuals (50%). In the first-line group, most patients
received 90Y-IT as consolidation (n = 44, 98%), while only 1
individual (2%) was administered 90Y-ITas a monotherapy as
first-line treatment. Likewise, in the relapse group, most pa-
tients (n = 24, 53%) received RIT as consolidation after
immunochemotherapy, 13 pat. received RIT for recurrence,
3 pts. for refractory disease and 2 pts. as part of a conditioning
regiment, and for 3 pts., indication for RIT is not documented
(Table 2). Of note, 90Y-IT was most often used as first-line
therapy (n = 45, 50%) and second-line therapy (n = 23, 26%),
while only 20 patients received RIT as third or higher lines of
treatment, and for 2 patients, line of therapy was not docu-
mented (Table 2). Radiotherapy prior to RIT was infrequent
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with 8 (9%) patients receiving radiotherapy before RIT. Most
pat ients had 1 (n = 34, 38%) or 2 (n = 28, 31%)
chemo( immuno) therap ies pr ior to RIT, whi le 3
chemo(immuno)therapies (n = 11, 12%), 4 (n = 7, 8%), 5
(n = 3, 3%) 6 (n = 1, 1%) and more than 7 (n = 2, 2%) were
less frequent (Table 1). Only 2 pts. had been previously treated
with RIT. Of note, in some patients, chemo- and immunother-
apy, e.g. COP and rituximab, given as first line, were counted
as two therapies. Similarly, omission of one drug from a reg-
imen, e.g. omission of doxorubicin from CHOP resulting in
CVP, was counted as two therapies in first line in some cases.
Therefore, not 44 but only 34 are listed in Table 1 to have
received one chemo(immune)therapy before obtaining 90Y-
IT.
At any rate, however, 44 patients received RIT as consoli-
dation after first-line immunochemotherapy, and one patient
obtained 90Y-IT without any prior treatment. None of the
patients had a Bruton’s kinase inhibitor like ibrutinib prior to
90Y-IT.
Response, duration of response and overall survival
For all patients, response data is only available after RIT. If
RIT was preceded by chemoimmunotherapy, which was fre-
quently the case, response was not typically evaluated directly
after induction therapy nor was such a response recorded in
the RIT registry. Therefore, information regarding conversion,
e.g. from PR after induction therapy to CR after RIT, is not
available from the RIT registry. For all patients (n = 90), the
best response was CR in 47 pts. (52%), PR in 16 pts. (18%),
SD in 2 pts. (2%) and PD in 7 pts. (8%). Accurate response
data were not reported for 18 pts. (20%). In the first-line group
with 45 patients, 30 pts. (67%) achieved complete remission
(CR), 10 pts. (22%) achieved partial remission (PR), 1 pt.
(2%) experienced progressive disease (PD), not documented
was response for 4 pts. (9%). For patients treated in relapse
(n = 45), the CR rate was 38%, PR was 13%, SD was 4% and
13% had PD, while the response was not documented for 31%
(n = 14 pts.) (Table 3). With a median follow-up of 5.5 years
(range 0–11.5 years), the median PFS for all patients was
2.11 years (95% CI, 1.03–2.32), and median OS was
4.05 years (95%CI, 2.79–7.21). For first-line patients, median
PFSwas 2.79 (95%CI, 2.14–3.79) years, while it amounted to
0.88 (95% CI, 0.66–1.5) years for relapsed patients.
Median OS in the first-line group was 4.05 years (95% CI,
3.15–7.9) and was 3.85 years (95% CI, 1.49–7.71) in the
relapse group (Fig. 1).
Second malignancies
With a median follow-up time of 5.5 years (range 0–
11.5 years), in 11 (12%) of the 90 patients, a second malig-
nancy evolved. In nine patients, second malignancy occurred
after first-line therapy, and all of these patients had an initial
fludarabine-containing regiment (fludarabine, cyclophospha-
mide [FC], rituximab-FC [R-FC] or R-FC mitoxantrone [R-
FCM]). In two patients, second malignancy occurred after 5th
and 6th line therapy. Time of onset of secondary malignancies
after RIT was not documented in the registry. Of the patients
with second malignancies, 6 (55%) suffered from
myelodysplastic syndrome (MDS), 2 from prostate cancer, 1
from oesophageal cancer, 1 from NSCLC and 1 from
rhabdomyosarcoma.
Table 1 Patient characteristics
No. of patients 90
Male/female 63 (70%)/27 (30%)
Median age (range) 63 (31–78)
n > 60 years 56 (62.2%)
n > 70 years 19 (21.1%)
Stage No. of patients (%)
n %
Stage IV 62 68.9%
Stage III 22 24.4%
Stage II 2 2.2%
Stage I 3 3.3%
Missing 1 1.1%
Previous therapies
Chemo(immuno)therapy n %
0 4* (4.4)
1 34* (37.8)
2 28 (31.1)
3 11 (12.2)
> 4 13 (14.4)
Radiotherapy n %
0 82 (91.1)
1 7 (7.8)
2 1 (1.1)
Autologous stem cell transplantation
n %
10 (11.11)
Indication for RIT
Line n %
First-line therapy 45 50
Primary therapy (RIT mono) 1 1.1
Consolidation (after first-line th.) 44 48.9
Relapse 45 50
Recurrence 12 13.3
Refractory 3 3.3
Conditioning 2 2.2
Consolidation 24 26.7
No indication 1 1.1
Other 3 3.3
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Discussion
The RIT registry (RIT-NT) is the largest registry of MCL
patients treated with 90Y-IT published to date. Half of the
90 patients reported herein received 90Y-IT as first-line ther-
apy, in most cases as consolidation after chemo- or
chemoimmunotherapy. For the remainder, 24 or 26% of
patients were given 90Y-IT as second-line treatment, in
most cases (15 of 24 pts.) as consolidation after
chemo(immuno)therapy.
Overall response rate and CR for patients with first-line
therapy were 89% and 67%, respectively. After a median
follow-up of 5.5 years, the median PFS and OS for pa-
tients treated in first line amounted to 2.79 and 4.05 years,
respectively. Toxicity was as expected no unexpected
safety signals were detected for employment of 90Y-IT
in mantle cell lymphoma. There are few studies
employing 90Y-IT as first-line therapy for MCL. In a pro-
spective multicentre trial, 34 patients with MCL were
treated as first line with distinct chemo(immuno)therapies
(FCM, FC, CHOP or CVP ± R) and received consolida-
tion with 90Y-IT upon achieving a predefined tumour re-
sponse after 3 to 6 cycles of treatment. 90Y-IT consolida-
tion improved the CR rate in chemosensitive patients from
41 to 91%, and the median PFS and OS amounted to 3.3
and 6.5 years, respectively [5]. In line with these findings,
57 MCL patients were treated in a prospective single-
centre trial with 90Y-IT if they had achieved at least stable
disease after four cycles of R-CHOP. Herein, the ORR
and CR rates were 82% and 52%, respectively, and the
median time to treatment failure (TTF) amounted to
34 months [8]. With a longer follow-up median of
9.8 years, median OS for the entire cohort of 56 patients
was 7.9 years. During follow-up, one myeloid neoplasia
and 6 solid malignancies (2 NSCLC, 1 bladder cancer, 1
ampullary cancer and 2 non-melanoma skin cancers) were
observed [4]. These results from 90Y-IT consolidation af-
ter shortened chemoimmunotherapy and data from the
RIT-NT presented compare well with data from MCL pa-
tients treated in clinical trials with six cycles of
chemoimmunotherapy with or without rituximab mainte-
n a n c e , i . e . c h emo immuno t h e r a p y w i t h R -B
(bendamustine), R-CHOP and VR-CAP with or without
rituximab maintenance. Here, ORR ranged between 86
and 93%, and the CR rate was between 30 and 53%.
Median PFS amounted to 35 months after R-B, ranging
from 14 to 22 months after R-CHOP and 24 months after
VR-CAP [9, 10]. Treatment of elderly MCP patients with
R-CHOP followed by rituximab maintenance induced a 4-
year remission duration of approximately 60% [2].
Therefore, an abbreviated chemoimmunotherapy followed
by 90Y-IT might be just as effective as six cycles of
chemoimmunotherapy with or without rituximab
maintenance.
In contrast, a phase 2 trial from the Nordic lymphoma
group did not show a benefit from applying 90Y-IT to MCL
patients who had only achieved PR after induction
chemoimmunotherapy with R-maxiCHOP and high-dose
cytarabine and were subsequently treated with HCT and
ASCT. Here, the data were compared to a previous trial where
patients received the same chemoimmunotherapy, including
HCT and ASCT, and did not get 90Y-IT. With respect to PFS
and OS, adding 90Y-IT did not improve the results [11], indi-
cating that 90Y-IT may not improve CR rates after intensive
induction chemoimmunotherapy.
Regarding relapsed MCL in the RIT-NT, the ORR and
CR rates for 90Y-IT as a monotherapy or as consolidation
Table 2 Indication for RIT and
line of therapy (n) Line of therapy
Indication First line Relapse
First All Second Third Fourth ≥ Fifth line
Conditioning 2 1 1
Consolidation 44 24 15 1 2 6
Primary therapy 1 0
Recurrence 12 5 2 1 4
Refractory 3 2 1
Other 4 1 1 1
All 45 (50%) 45 (50%) 24 (25.5%) 5 (5.5%) 3 (3.3%) 12 (13.3%)
Table 3 Response according to indication
Best response All patients First line Relapse
n (%) n (%) n (%)
CR 47 (52.2) 30 (66.7) 17 (37.8)
PR 16 (17.8) 10 (22.2) 6 (13.3)
SD 2 (2.2) 0 2 (4.4)
PD 7 (7.8) 1 (2.2) 6 (13.3)
Missing 18 (20) 4 (8.9) 14 (31.1)
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after chemo(immuno)therapy were 51% and 38%, respec-
tively. Median PFS and OS amounted to 0.88 and
3.85 years, respectively. There are little data from pro-
spective clinical trials employing 90Y-IT in patients with
relapsed MCL. In the aforementioned multicentre trial [5],
12 pat ients received 90Y-IT consol idat ion after
r e s p o n d i n g t o 3 – 6 c y c l e s o f s e c o n d - l i n e
chemo(immune)therapy. Subsequent to 90Y-IT, the CR
rate increased from 16 to 75% in the trial reported by
Jurzak et al. [5], resulting in a median PFS and OS of
1.8 and 2.2 years, respectively. In a small trial with re-
lapsed or refractory MCL patients with a median of 3
prior therapies, including high-dose chemotherapy
(HCT) and autologous stem cell transplantation (ASCT),
90Y-IT was applied as a monotherapy in 16 patients and
as consolidation after chemoimmunotherapy in 32 indi-
viduals. The overall response rate and CR for the entire
patient cohort were 61 and 32%, respectively, and the
median PFS and OS amounted to 6.2 and 25.5 months,
respectively. When 90Y-IT was employed as consolida-
tion, the ORR and CR rates were higher in comparison
to 90Y-IT monotherapy, i.e. ORR 72 compared to 40%
and CR 38 compared to 20%, respectively. The same
was true for PFS and OS, i.e. PFS was 8.9 compared to
3.7 months and OS of 31.2 compared to 13.8 months [6].
In a single-centre trial with 90Y-IT monotherapy for pa-
tients with relapsed or refractory MCL and a median of 3
prior therapies, the ORR was 31%, CR was 15%, PFS
was 6 months, and OS was 21 months. Interestingly,
PFS in patients with either CR or PR amounted to
28 months. These data indicate that 90Y-IT may be more
effective as consolidation after chemo(immune)therapy
and has probably little effect if employed as monotherapy
at relapse [12]. Unfortunately, there is no data available
from the RIT-NT regarding the response rate prior to 90Y-
IT consolidation to strengthen this notion, as response
rates were exclusively reported after 90Y-IT.
In line with our data, PFS and OS for the whole group
of relapsed or refractory patients amounted to 0.88
(10.8 months) and 3.85 years (46 months). In comparison,
the Bruton’s kinase inhibitor ibrutinib alone induced a
median PFS of 13.9 and 15.8 months after a median of
three or two prior therapies and median follow-up of
15.3 months and 39 months, respectively, in two prospec-
tive clinical trials [13–15]. Overall survival amounted to
58% at 18 months and a median of 30.3 months in these
two clinical studies, respectively. This demonstrates the
efficacy of ibrutinib and underscores its role in relapsed
or refractory MCL.
In conclusion, we report results from the largest regis-
try of MCL pts. treated with 90Y-IT to date. Our data and
results from prospective clinical trials demonstrate that
90Y-IT containing treatment of mantle cell lymphoma is
f e a s i b l e a nd a ch i e v e s r e s u l t s c ompa r a b l e t o
a
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Fig. 1 Progression-free survival (PFS, top) and overall survival (OS, bottom) for all patients (a) or patients on first-line therapy or with relapse (b)
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chemoimmunotherapy. Data from clinical trials indicate
that 90Y-IT may improve clinical results and may facili-
tate fewer cycles of chemoimmunotherapy. In our study,
as a limitation of the registry data, response rates after
induction chemoimmunotherapy, i.e. before 90Y-IT con-
solidation, were not reported. Therefore, we cannot tell
whether 90Y-IT, when given as a consolidation after induction
chemoimmunotherapy, improved the response rate achieved
by induction treatment. To further elucidate this issue, a pro-
spective clinical trial would be required. Of note, the results
with 90Y-IT after chemoimmunotherapy at relapse are far less
encouraging compared to treatment with small molecules such
as ibrutinib.
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